Key Events This Week
16 Feb: Stock opens at Rs.241.05, modest gain of 0.61%
17 Feb: Technical momentum shifts mildly bullish, price rises to Rs.245.00 (+1.64%)
18 Feb: Mixed technical signals emerge amid sideways momentum, price dips to Rs.238.95 (-2.47%)
19 Feb: Downgrade to Sell rating announced; stock declines 0.40% to Rs.238.00
20 Feb: Slight recovery to Rs.239.05 (+0.44%) as week closes
16 February 2026: Modest Opening Gains Amid Positive Market Sentiment
Artemis Medicare Services Ltd began the week on a positive note, closing at Rs.241.05, up 0.61% from the previous Friday’s close of Rs.239.60. The stock’s volume was moderate at 6,329 shares, while the Sensex advanced 0.70% to 36,787.89. This initial uptick aligned with broader market optimism, setting a cautiously positive tone for the week ahead.
17 February 2026: Technical Momentum Shifts to Mildly Bullish, Price Peaks at Rs.245.00
On 17 February, Artemis Medicare’s technical momentum shifted from sideways to mildly bullish, supported by improving daily moving averages and bullish RSI readings. The stock closed at Rs.245.00, gaining 1.64% on the day, outperforming the Sensex’s 0.32% rise to 36,904.38. Despite this, the MACD remained bearish on weekly and monthly charts, signalling that the upward momentum was tentative. The stock traded within a range of Rs.234.05 to Rs.243.45, well below its 52-week high of Rs.305.95 but comfortably above the 52-week low of Rs.208.75.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
18 February 2026: Mixed Technical Signals Amid Sideways Momentum
The following day, the stock reversed course, closing at Rs.238.95, down 2.47% from the previous close. Despite a modest gain reported in one source of 1.47%, the overall price action reflected a softening of momentum. Technical indicators presented a mixed picture: daily moving averages remained mildly bullish, but weekly and monthly MACD and KST oscillators turned bearish. Bollinger Bands suggested price consolidation, while RSI readings stayed bullish, indicating some underlying buying interest. The Sensex continued its upward trend, gaining 0.43% to 37,062.35, highlighting Artemis Medicare’s relative underperformance.
19 February 2026: Downgrade to Sell Amid Technical Weakness and Market Underperformance
On 19 February, MarketsMOJO downgraded Artemis Medicare from a Hold to a Sell rating, citing deteriorating technical indicators and persistent underperformance relative to the broader market. The stock closed at Rs.238.00, down 0.40%, while the Sensex fell sharply by 1.45% to 36,523.88. Despite strong financial fundamentals—including a 27.19% growth in six-month PAT to Rs.54.60 crores, an 84.98% annual rise in operating profit, and healthy ROCE of 13.34%—the downgrade reflected concerns over technical momentum shifting to mildly bearish and a high promoter share pledging level of 44.53%, which poses additional risk in volatile markets.
20 February 2026: Slight Recovery as Week Closes
The week ended with a modest recovery, as Artemis Medicare closed at Rs.239.05, up 0.44% on the day, while the Sensex gained 0.41% to 36,674.32. Technical indicators remained mixed, with daily moving averages mildly bullish but weekly and monthly MACD and KST oscillators still bearish. The On-Balance Volume (OBV) suggested selling pressure persisted, and Dow Theory analysis indicated no clear trend on the weekly chart and a mildly bearish stance monthly. The stock’s price remained closer to its 52-week low of Rs.208.75 than its high of Rs.305.95, underscoring the cautious environment.
Artemis Medicare Services Ltd or something better? Our SwitchER feature analyzes this small-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Weekly Price Performance: Artemis Medicare vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-16 | Rs.241.05 | +0.61% | 36,787.89 | +0.70% |
| 2026-02-17 | Rs.245.00 | +1.64% | 36,904.38 | +0.32% |
| 2026-02-18 | Rs.238.95 | -2.47% | 37,062.35 | +0.43% |
| 2026-02-19 | Rs.238.00 | -0.40% | 36,523.88 | -1.45% |
| 2026-02-20 | Rs.239.05 | +0.44% | 36,674.32 | +0.41% |
Key Takeaways
Positive Signals: Artemis Medicare showed short-term resilience with daily moving averages and RSI indicators maintaining mild bullishness during parts of the week. The stock’s long-term performance remains impressive, with three-year and five-year returns exceeding 250% and 800% respectively, far outpacing the Sensex. Financial fundamentals are strong, with consistent earnings growth, healthy profitability ratios, and conservative debt levels.
Cautionary Signals: The downgrade to a Sell rating by MarketsMOJO on 18 February reflects deteriorating technical momentum, with weekly and monthly MACD, KST, and Bollinger Bands signalling bearish trends. The stock underperformed the Sensex over the week and longer periods, and promoter share pledging at 44.53% adds structural risk. Volume trends and On-Balance Volume indicators suggest selling pressure, and Dow Theory analysis points to a lack of clear trend direction.
Conclusion
Artemis Medicare Services Ltd’s week was characterised by a complex interplay of technical shifts and fundamental strengths. While short-term indicators showed intermittent bullishness, the overall technical momentum weakened, culminating in a downgrade to Sell. The stock’s marginal weekly decline of 0.23% contrasted with the Sensex’s 0.39% gain, underscoring relative underperformance amid a cautious market environment. Investors should weigh the company’s robust financial profile and long-term growth record against the current technical headwinds and elevated promoter pledging risks. Vigilant monitoring of key support and resistance levels, alongside volume and momentum indicators, will be essential in assessing the stock’s near-term trajectory within the hospital sector.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
